Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."

ADVOCACY UPDATES

Your AAOA at the AMA

I want to urge you to consider membership in the AMA because your membership in…

read more

Fall Advocacy Update: USP 797, E/M Documentation and Payment

Revisions to USP Chapter 797 Open for Comment Since the United States Pharmacopeia (USP) released…

read more

Brief Update on the Final CY 2019 Physician Fee Schedule

On November 1, the Centers for Medicare and Medicaid Services released the final Physician Fee…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

12/01/2018: Research Grant Cycle
Learn more

04/01/2019: 2019 Fellow Exam Application Deadline
Learn more

06/01/2019: Research Grant Cycle

06/7/19: Membership Application Deadline to be eligible for AAOA Member rate for the 2019 Basic Course

07/31/19: Membership Application Deadline to be voted in at the 2019 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2019 Annual Meeting
Learn more

EDUCATION

Codes/Guidelines

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

IFAR

IFAR Impact Factor: 2.135

aaoaf-ifar

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2019 Interactive Allergy & Rhinology Course
February 8-10, 2019 | Dallas, TX
Learn More and Register

2019 Basic Course in Allergy & Immunology
June 27-29 | Minneapolis, MN
Save the Date

2019 AAOA Annual Meeting
September 13-15 | New Orleans, LA
Save the Date

2019 Advanced Course in Allergy & Immunology
December 12-14 | Austin, TX
Save the Date

AAOA Clinical Insights
Learn More and Register

PATIENT CORNER

OTC Allergy Medications

There seem to be more and more medications available for allergy treatment that  you can now purchase over the counter.
The FDA is allowing previously prescription only drugs to be made available directly to the consumer without a prescription — adding more to the over-the-counter options in the healthcare aisles.

Read More

News and Updates

From the AAOA President, Matthew Ryan, MD

...the AAOA continues to be the organization that Otolaryngologists look to for up-to-date education and information on the…

read more

FDA Approves First Generic Version of EpiPen

The Food and Drug Administration approves the first generic version of EpiPen and EpiPen Jr.…

read more

Social and Networking Events at the 2018 AAOA Annual Meeting

This year’s Annual Meeting assures to be not only educational, interactive, and practice-centered, but also…

read more

Menu

Your AAOA at the AMA

I want to urge you to consider membership in the AMA because your membership in AMA gives us a voice.

The American Medical Association is one organization that the AAOA works through to advocate for issues related to the AAOA.   As a national specialty society, your membership in the AMA is what gives us our seat — which gives us a voice on your behalf.  This seat goes beyond our AMA House of Delegates delegation.  It gives us a seat at CPT, RUC, and PERC as well.   Without a seat in the AMA, we would not be able to participate in these other regulatory bodies.

Through our involvement in the AMA, we have been able to collaborate with AAAAI and  ACAAI to oppose change in the proposed changes to USP 797 concerning physician allergy compounding that was put forth 2 years ago.  Those joint efforts resulted in halting the change in USP policy and causing USP to revamp recommendations. USP 797 and issues around physician compounding at the FDA are key examples of issues where AAOA’s participation in national coalitions and working with AMA have been instrumental in helping to assure you can deliver quality care.

Through this advocacy effort and the work of our Socioeconomic Committee, we were invited two years ago by the ACAAI leadership to participate on its Advocacy Council of the ACAAI.  Again, broadening our voice and impact on allergy patient care.

Our AMA seat does broaden our opportunities in the House of Medicine.  Networking is key in managing issues at the AMA.  Your AAOA delegation is actively involved in the Chest/Allergy Caucus.  In fact, we will chair this caucus beginning in 2019.  This caucus brings together all the specialties involved in airway management — Chest, Thoracic, Sleep, Allergy, Critical Care, and Pulmonology.  In the House, this caucus has been instrumental in joining forces on issues around physician compounding, tobacco, allergy, food allergy and labeling, over-the-counter medications, and many others.

We also sit on the Otolaryngology Section Council with our peer societies within otolaryngology — AAOHNS, AAFPRS, Triologic, and now ARS — as well as all the otolaryngologists who represent their states in the House of Medicine.  Coalescing these key delegates helps assure specialty interests and state interests are considered together to help achieve better results.

As a specialty society in the AMA House, we have a seat in the Specialty and Service Section, which gives us the opportunity for multiple specialty societies to unite on issues.

The AMA 2018 Interim House of Delegates meeting is just ending in Washington, DC.   Several key issues tied to tobacco, food allergy, CMS, E/M coding, CHIP reauthorization, and more were considered.  The Chest/Allergy caucus was effective in bringing an emergency resolution regarding the FDA’s recent (11/6) decision to put Primatene Mist, an antiquated medication, back on the market as an over-the-counter product to treat mild and intermittent asthma.  While originally pulled due to its delivery mechanism impacting the ozone layer, Primatene Mist, a nonspecific beta agonist or epinephrine, has not been defined as a therapeutic pathway of choice for the management of asthma in any national or international  asthma guideline.  Risk of patient self medication, cardio-vascular risk, and payor issues were all flagged as potential bad, unintended outcomes of pushing Primatene Mist back on the market.  Additionally, issues were raised regarding the FDA process and lack of a public comment period to allow for input, and the AMA will take action with the FDA to urge them to reconsider their decision.

So while you may not always agree with the AMA on issues or want to add yet another dues to your professional costs, our seat is tied to our membership numbers in AMA.  Specialty societies are required to have at least a 20% AMA membership to have a seat.  Your membership in AMA gives us a voice — both on issues with which we agree with AMA and those with which we do not.  Please consider becoming a member of the AMA so we can maintain our seat in the AMA in 2019.

Wes VanderArk, MD, FAAOA
AAOA AMA Delegate